Decisions about anticoagulation means balancing the benefit of stroke reduction against the risk of haemorrhage using scoring systems.
Before starting anticoagulation, clinicians should use a stratification scheme for stroke and haemorrhage to help balance the risks and benefits.6 The ESC/EHRA guidelines recommend the CHA2DS2-VASc (Table 6 and Figure 18) score to predict stroke risk in AF patients.
Table 6. CHA2DS2-VASc scoring system for assessing stroke risk.6
In addition, clinicians should use a bleeding risk stratification scheme, such as HAS-BLED (Table 7 and Figure 18) to assess haemorrhage risk and identify risk factors (Table 8) for major bleeding in people taking anticoagulants. Biomarkers, such as high-sensitivity troponin and natriuretic peptide, can help further assess the risk of stroke and bleeding risk in AF.5
Table 7. HAS-BLED scoring system for assessing haemorrhage risk.5
Table 8. Risk factors for haemorrhage in patients taking anticoagulants.5,38
The next section features an introduction to anticoagulation therapy
Alternatively login via
Back to epgonline.org